JAK-STAT-IN-1

CAS No. 1236666-76-4

JAK-STAT-IN-1( —— )

Catalog No. M37203 CAS No. 1236666-76-4

JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 296 Get Quote
5MG 459 Get Quote
10MG 657 Get Quote
25MG 994 Get Quote
50MG 1371 Get Quote
100MG 1773 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    JAK-STAT-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    JAK-STAT-IN-1 is a specific JAK-STAT inhibitor indicated for the study of autoimmune diseases.
  • Description
    JAK-STAT-IN-1 (compound 1) is a selective JAK-STAT inhibitor. JAK-STAT-IN-1 can be used for the research of autoimmune disorder.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK | STAT
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1236666-76-4
  • Formula Weight
    375.42
  • Molecular Formula
    C21H21N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C1OC2=CC=C(C=C2N1)NC3=NC(=NC=C3C)NC=4C=C(C(=C(C4)C)C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Llinas A , et al. Derisking Development by a Cocrystallization Screen of a Novel Selective Inhaled JAK-STAT inhibitor[J].Crystal Growth And Design, 2019, 19(1):403-414.
molnova catalog
related products
  • CEP-33779

    CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.

  • Tyk2-IN-30

    TYK2-IN-30 is a potent, selective and orally active Tyk2 inhibitor with Ki of 0.7 nM.

  • Axltide

    Axltide is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).Peptide sequence (KKSRGDYMTMQIG) is based on the mouse Insulin receptor substrate 1 (amino acid 979-989).